Fresenius completes mAbxience deal as Fresenius stock gains 1.47 percent

Published on 10/05/2026 at 13:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue rose 6.00 percent to EUR 5.864 billion. Fresenius stock costs EUR 44.32 on October 5, 2026 versus EUR 43.68, plus 1.47 percent.

Fresenius SE – Fotorealistisch: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht — Fresenius SE & Co. KGaA (ISIN DE0005785604) ist ein internationaler Gesundheitskonzern mit Sitz in Bad Homburg. Das Unternehmen betreibt Krankenhäuser und entwickelt Arzneimittel und Infusionslösungen. Dieses Bild zeigt: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht, Illustration mit AI erstellt.

Fresenius stock (ISIN DE000FRE5EN2) was trading at EUR 44.32 at Lang & Schwarz on October 5, 2026 at 1:15 p.m. CEST, up 1.47 percent versus the prior close of EUR 43.68. The company completed its acquisition of the remaining 45 percent of mAbxience for consideration of up to EUR 750.0 million on September 30, 2026, according to Fresenius.

mAbxience adds full ownership

The transaction gives Fresenius full ownership of the biosimilars platform through Fresenius Kabi. The consideration includes a contingent payment of EUR 50.0 million, while no new financing was required, the October 1, 2026 release said.

mAbxience generated more than EUR 320.0 million in revenue in fiscal year 2025 and operates three manufacturing facilities in Spain and Latin America. Its portfolio includes four products on the market and eight candidates in development, giving the deal an operating platform rather than only a financial effect.

Second-quarter growth supports the deal

Fresenius reported revenue of EUR 5.864 billion in the second quarter of 2026, up 6.00 percent from EUR 5.571 billion in the second quarter of 2025. The company also reported EBIT of EUR 719.0 million, up 10.00 percent from EUR 654.0 million, and core net income of EUR 470.0 million, up 14.00 percent from EUR 412.0 million, according to Fresenius in its investor-relations materials.

The acquisition release kept full-year 2026 guidance unchanged and said the transaction should be immediately accretive to Group core earnings per share. That combination makes the deal strategically relevant while leaving the existing annual outlook intact.

Target remains above the market price

UBS maintained a Buy rating and a EUR 56.00 price target on September 7, 2026, according to FinanzNachrichten. The target lies 26.35 percent above the Lang & Schwarz price, while UBS estimated that concerns about the Tyenne biosimilar could affect operating group earnings by 0.30 percent at most.

Fresenius had a market capitalization of EUR 24.9 billion as of October 5, 2026 at 1:06 p.m. CEST. Its 52-week range was EUR 35.11 to EUR 52.96, leaving the Lang & Schwarz price 16.31 percent below the yearly high.

Next results date is November 4

Fresenius lists November 4, 2026 as the date for its third-quarter 2026 results. The upcoming report will show whether the second-quarter pattern of 6.00 percent revenue growth and 10.00 percent EBIT growth continued into the next reporting period.

The further course of trading is shown by the continuously updated real-time quote of Fresenius stock.